On October 17, 2024 Nusano, a physics company transforming the production of radioisotopes, and Starget Pharma, a clinical-stage biotechnology company developing precision peptide radioligand therapies focused on difficult to treat cancers, reported a supply agreement to advance the development of Starget’s Smart Targeted Radioligands (STRs) (Press release, Nusano, OCT 17, 2024, View Source [SID1234647247]). The supply agreement is expected to support Starget’s STR isotope needs from discovery through commercialization and will include both common radioisotopes as well as rare alpha particle-emitters such as Astatine-211, Lead-212, and Actinium-225.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to partner with Nusano, a leader in radioisotope production, to support the development of our novel pipeline of smart targeted radioligands," said Sigal Kalmanson Cusnir, CEO of Starget Pharma. "Our STR platform technology enables the rapid design and evaluation of radiotherapies in an isotope-agnostic manner, allowing us to optimize performance by tumor type. We are focused now on advancing our clinical pipeline, beginning with the planned initiation of a Phase 1b clinical trial in early 2025. The Nusano agreement will ensure that we have a reliable radioisotope supply chain, facilitating near and long term growth, with the ultimate goal of radically improving patient care and outcomes."
Starget’s STR platform is advancing the field of molecular radiation using its proprietary backbone cyclization technology to create innovative and diversified peptide radioligand candidates with enhanced properties. These STRs are designed to bind and deliver a payload of radiation specifically to biological targets that are overexpressed in cancer compared to normal cells. This highly focused radiation then damages the DNA in the cancer cells, leading to selective cell death and tumor shrinkage. Due to their unique molecular interaction with the target, STRs act with high sensitivity and precision, enabling effective radiation targeting tumors and metastasis.
Radioisotopes are essential components in the active pharmaceutical ingredients (API) used in new and emerging cancer therapies including molecular radiation. Existing supply chains for these treatment-enabling resources are often strained, posing a risk to patient care, clinical trials, and ongoing drug development.
Nusano is working to stabilize supply chains and enable innovation by bringing new sources of radioisotopes to medical and industrial markets. Opening in 2025 in West Valley City, Utah, the Nusano production platform will be capable of generating more than 25 radioisotopes applicable to medical and industrial uses. It is anchored by a proprietary ion source technology which accelerates heavy particles (alphas and deuterons) to generate high volume, high quality (cGMP-grade) radioisotopes with unparalleled efficiency using eco-friendly methods. The result is one of the first significant advancements in radioisotope production in decades.
Chris Lowe, CEO of Nusano commented, "The Nusano platform will make medical radioisotopes available in varieties and volumes needed to broaden and accelerate radiotherapeutics development. We share Starget’s enthusiasm for finding the right isotope to target specific tumor types and look forward to working with them to advance more isotopes into clinical development for the betterment of cancer patients around the world."